Astellas Pharma, Inc.
Latest Astellas Pharma, Inc. News and Updates

How the Voya Japan TOPIX Index Portfolio Class A Fared in September 2015
The Voya Japan TOPIX Index Portfolio fell by 6.7% in September 2015 from the previous month.
Stock Selection Saves the Nuveen Tradewinds Japan Fund – A
The Nuveen Tradewinds Japan Fund – A (NTJAX) fell 4.4% in August from a month ago. In the three-month period ended August 31, it fell 2.1%, the third least faller.

Understanding FibroGen’s Research Pipeline
Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

A Look at Novartis’s Immunology and Dermatology Segment’s Performance
In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.

How Did Merck’s Invanz and Cancidas Perform in 2017?
In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis.

Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

Why Lupron Could Continue to Generate Steady Revenue
In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.
Depressed Consumer Spending Hurt the Fidelity Advisor Overseas Fund
The Fidelity Advisor Overseas Fund – Class A (FAOAX) has emerged as a below-average performer in YTD 2016 among the 12 funds chosen for this review.

What’s the Sector Composition of the Fidelity Advisor Overseas Fund?
The Fidelity Advisor Overseas Fund invests at least 80% of its net assets in common stocks of non-US issuers.

The Fidelity Advisor Overseas Fund’s Portfolio Moves in YTD 2016
The Fidelity Advisor Overseas Fund’s (FAOAX) top sectoral bet is the consumer discretionary sector, which forms one-fourth of the fund’s total assets.

Healthcare Stocks Save the Day for CNJFX
Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

How Are Drugs Priced in Japan?
The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

What’s the Drug Approval Process in Japan?
The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

What You Should Know about the Fidelity Advisor Overseas Fund
The Fidelity Advisor Overseas Fund – Class A (FAOAX) was incepted in September 1996 and has an expense ratio of 1.4%.

Get Your Essentials on the Invesco Pacific Growth Fund (TGRAX)
The Invesco Pacific Growth Fund, under normal circumstances, will invest “at least 80% of its net assets in securities of issuers in the Pacific region.”

Meet the Columbia Pacific/Asia Fund (CASAX)
The Columbia Pacific/Asia Fund (CASAX) aims to invest 80% of its net assets in equity securities of companies “located in Asia and the Pacific Basin.

A Portfolio Scan of the T. Rowe Price Japan Fund in 2015
The T. Rowe Price Japan Fund (PRJPX) is well diversified with 78 holdings as of December 2015. It was managing assets worth $330.08 million at the end of December.

A Portfolio Scan of the Fidelity Japan Fund in 2015
The Fidelity Japan Fund’s (FJPNX) assets were spread across 86 securities as of December 2015 and it was managing $545.18 million in assets.

Market Response to Xalkori’s Label Update
Observing the changes in Pfizer’s stock price after Xalkori’s label update by the European Commission shows that the stock price rose by ~2.8%.

Pfizer’s Xalkori Approved by the European Commission
Pfizer’s oncology drug Xalkori, also termed Crizotinib, was approved for label expansion and label update by the European Commission on November 25.

Insight on Profile 1014: Phase III Study for Xalkori
Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer’s press release, study was a randomized, and involved 343 patients.

The Voya Japan TOPIX Index Portfolio Class A (IJIAX): Historical Overview
The Voya Japan TOPIX Index Portfolio Class A is an index fund, not an actively managed mutual fund, so it necessarily tracks its benchmark index.

Assessing the Fidelity Japan Fund (FJPNX): Historical Overview
The Fidelity Japan Fund invests at least 80% of its assets in securities of Japanese issuers and other investments that are tied economically to Japan.